Tolerizing agents

Details Tolerizing agents Tolerizing agents

2011-03-22

2011-03-22

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S184100, C424S192100, C530S350000

Reexamination Certificate

active

07910113

ABSTRACT:
Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a pσ1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity.

REFERENCES:
patent: 6072041 (2000-06-01), Davis et al.
patent: WO 2006/052668 (2006-05-01), None
patent: WO 2006/078567 (2006-07-01), None
Allan et al. “Rat intestinal M cells contain acidic endosomal-lysosomal compartments and express class II major histocompatibility complex determinants,”Gastroenterology, 104:698-708, 1993.
Barton et al., “Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening,”J Biol Chem, 276:2200-2211, 2000.
Chappell et al., “Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein σ1,”J. Virol, 71:1834, 1997.
Chen et al., “Peripheral deletion of antigen-reactive T cells in oral tolerance,”Nature, 376:177-180, 1995.
Chen et al., “Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis,”Science, 265:1237-1240, 1994.
Collins et al., “Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock,”Infect Immun, 70:2282-2287, 2002.
Cottrez and Groux, “Specialization in tolerance: innate CD4+ CD25+ versus acquired Tr1 and Th3 regulatory T cells,”Transplantation, 77:S12-15, 2004.
Dieckmann et al., “Human CD4+ CD25+ regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected],”J Exp Med, 196:247-253, 2002.
Ermak et al., “Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells,”Cell Tissue Res, 279:433-436, 1995.
Friedman and Weiner, “Induction of anergy or active suppression following oral tolerance is determined by antigen dosage,”Proc Natl Acad Sci(USA), 91:6688-6692, 1994.
Frisoni et al., “Nuclear Autoantigen Translocation and Autoantibody Opsonization Lead to Increased Dendritic Cell Phagocytosis and Presentation of Nuclear Antigens: A Novel Pathogenic Pathway for Autoimmunity?,”J Immunology, 175:2692-2701, 2005.
Fujihashi et al., “A revisit of mucosal IgA immunity and oral tolerance,”Acta Odontol Scand, 59:301-308, 2001.
Fujihashi et al., “g/d T cell-deficient mice have impaired mucosal immunoglobulin A responses,”J Exp Med, 183:1929-1935, 1996.
Fujihashi et al., “Peyer's patches are required for oral tolerance to proteins,”Proc Natl Acad Sci(USA), 98:3310-3315, 2001.
Garside et al., “Oral tolerance in disease,”Gut, 44:137-142, 1999.
Gebert et al., “M cells in Peyer's patches of the intestine,”Int Rev Cytol, 167:91-159, 1996.
Groux et al., “A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis,”Nature, 389:737-742, 1997.
Gutgemann et al., “Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen,”Immunity, 8:667-673, 1998.
Hagiwara et al., “Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue,”J Immunol, 170:1754-1762, 2003.
Hamada et al., “Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine,”J Immunol, 168:57-64, 2002.
Holt, “Mucosal immunity in relation to the development of oral tolerance/sensitization,”Allergy, 53:16-19, 1998.
Jang et al., “Intestinal villous M cells: an antigen entry site in the mucosal epithelium,”Proc Natl Acad Sci(USA), 101:6110-6115, 2004.
Jones et al., “Salmonella typhimuriuminitiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches,”J Exp Med, 180:15-23, 1994.
Kataoka et al., “Nasal Flt3 ligand cDNA elicits CD11c+ CD8+ dendritic cells for enhanced mucosal immunity,”J Immunol, 172:3612-3619, 2004.
Kato et al., “Lack of oral tolerance in aging is due to sequential loss of Peyer's patch cell interactions,”Int Immunol, 15:145-158, 2003.
Kato et al., “Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses,”J Immunol, 166:3114-3121, 2001.
Koenen et al., “A novel bispecific antihuman CD40/CD86 fusion protein with t-cell tolerizing potential,”Transplantation, 78(10):1429-1438, 2004.
Krug et al., “TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function,”Immunity, 21:107-119, 2004.
MacDonald, “T cell immunity to oral allergens,”Curr Opin Immunol, 10:620-627, 1998.
Maddaloni et al., “Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A1,”J Immunology, 177(8):5524-5532, 2006.
Mayer, “Oral tolerance: new approaches, new problems,”Clin Immunol, 94:1-8, 2000.
Melamed and Friedman, “Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin,”Eur J Immunol, 23:935-942, 1993.
Monfardini et al., “Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes,”J Neuroimmunol, 123:123-134, 2002.
Mowat, “Anatomical basis of tolerance and immunity to intestinal antigens,”Nat Rev Immunol, 3:331-341, 2003.
Nagler-Anderson and Shi, “Peripheral nonresponsiveness to orally administered soluble protein antigens,”Crit Rev Immunol, 21:121-131, 2001.
Nagler-Anderson et al., “Control freaks: immune regulatory cells,”Nat Immunol, 5:119-122, 2004.
Neutra et al., “Epithelial M cells: gateways for mucosal infection and immunization,”Cell, 86:345-348, 1996.
Ochoa-Reparaz et al., “Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis,”J Immunol, 178(3):1791-1799, 2007.
Rubas et al., “Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro,”J Microencapsul, 7:385-395, 1990.
Spahn et al., “Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches,”Eur J Immunol, 32:1109-1113, 2002.
Strobel and Mowat, “Immune responses to dietary antigens: oral tolerance,”Immunol Today, 19:173-181, 1998.
Strober et al., “Oral tolerance,”J Clin Immunol, 18:1-30, 1998.
Sun et al., “Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance,”Proc Natl Acad Sci(USA), 91:10795-10799, 1994.
Tomasi, “Oral tolerance,”Transplantation, 29:353-356, 1980.
Tsuji et al., “Antigen-specific, CD4+ CD25+ regulatory T cell clones induced in Peyer's patches,”Int Immunol, 15:525-534, 2003.
Viney, et al., “Expanding dendritic cells in vivo enhances the induction of oral tolerance,”J Immunol, 160:5815-5825, 1998.
Wardrop and Whitacre, “Oral tolerance in the treatment of inflammatory autoimmune diseases,”Inflamm Res, 48:106-119, 1999.
Weiner et al., “Oral tolerance: immunologic

Affiliated with

Also associated with

Rating

Tolerizing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tolerizing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tolerizing agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675073